New antibody drug ESG206 tested for Hard-to-Treat blood cancers
NCT ID NCT05263739
First seen Nov 01, 2025 · Last updated May 13, 2026 · Updated 23 times
Summary
This early-phase study tested a new drug called ESG206 in adults with advanced B-cell blood cancers that had stopped responding to standard treatments. The main goal was to check the drug's safety and find the best dose. However, the study was withdrawn before any participants were enrolled.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for B-CELL LYMPHOID MALIGNANCIES are added.
By submitting, you agree to our Terms of use
Conditions
Explore the condition pages connected to this study.